X
KEY PRODUCTS KEY SERVICES
Details:
Under the terms of the collaboration, Novasep and Paratek will manufacture NUZYRA® (omadacycline), an FDA-approved tetracycline-class, once-daily oral and intravenous antibiotic for the treatment of adults with CABP and acute bacterial skin and skin structure infections.
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Paratek Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.
Lead Product(s): Monomethyl Auristatin E-Conjugated Antibody
Therapeutic Area: Oncology Product Name: Adcitmer
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: McSAF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 18, 2021
Cophex 2024
Not Confirmed
Contact Supplier
Details:
The received FDA approval will allow Breckenridge, to launch generic Teriflunomide in the US market from the beginning of 2023 onwards. Teriflunomide, a small molecule is a generic of Aubagio® available in 7mg & 14mg Tablets.
Lead Product(s): Teriflunomide
Therapeutic Area: Immunology Product Name: Teriflunomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Breckenridge Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Novasep will be in charge of developing and manufacturing the two AAV vectors designed for the Sensorion OTOF-GT project and will supply Drug Product batches to support preclinical and clinical studies.
Lead Product(s): OTOF-GT,Aav Vectors
Therapeutic Area: Genetic Disease Product Name: OTOF-GT
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sensorion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3.
Lead Product(s): LYS-GM101
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lysogene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 26, 2020
Cophex 2024
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Axplora- The partner of choice for complex APIs.
